Todd Franklin Watanabe sold $327k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 25,015 shares at an average of $13.07, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +15RoleOfficer
- +15Trade size$327k at market
- 0Share of holdings soldSold 2.6% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001787306-25-000042, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | AGrant or award Common Stock10b5-1 | +151,000 | $0.00 | $0 | 955,129 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -20,880 | $13.03 | $272k | 934,249 | Mar 4, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -4,135 | $13.28 | $55k | 930,114 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +396,000 | $0.00 | $0 | 396,000 | Mar 4, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 6Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $136k 10,139 shares | -8% | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $35k 2,646 shares | +11% | |
| 32Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $30k 2,268 shares | +10% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $25k 1,800 shares | -1% | |
| 38Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $69k 5,040 shares | +29% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $105k 7,451 shares | -4% | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $34k 2,520 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.